The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Influence of WNT and DNA damage response pathway alterations on outcomes in patients with unresectable metastatic colorectal cancer.
 
Sebastian Mondaca
Travel, Accommodations, Expenses - Roche; Roche
 
Henry S Walch
No Relationships to Disclose
 
Subhiksha Nandakumar
No Relationships to Disclose
 
Walid K. Chatila
No Relationships to Disclose
 
Jaclyn Frances Hechtman
Honoraria - Medscape
Consulting or Advisory Role - Axiom Biotechnologies; Navigant Consulting
Research Funding - Bayer
 
Andrea Cercek
Consulting or Advisory Role - Amgen; Bayer
Research Funding - Abbvie; Amgen; Bayer
 
Luis A. Diaz
Leadership - Jounce Therapeutics; Personal Genome Diagnostics
Stock and Other Ownership Interests - Jounce Therapeutics; PapGene, Inc.; Personal Genome Diagnostics; Zydecom
Consulting or Advisory Role - Caris Life Sciences; Cell Design Labs; Genocea Biosciences; Lyndra Therapeutics; Merck; Personal Genome Diagnostics; Phoremost; Zydecom
Research Funding - Merck (Inst)
Patents, Royalties, Other Intellectual Property - EP-2912468-B1 - Papanicolaou test for ovarian and endometrial cancers; EP-3322824-A1 - Detection of tumor-derived dna in cerebrospinal fluid; US-2005202465-A1 - Thymidylate synthase gene and metastasis; US-2010041048-A1 - Circulating Mutant DNA to Assess Tumor Dynamics; US-2013323167-A1 - Detecting and treating solid tumors through selective disruption of tumor vasculature; US-2014227271-A1 - Somatic mutations in atrx in brain cancer; US-2015252415-A1 - Arid1b and neuroblastoma; US-2015344970-A1 - Personalized Tumor Biomarkers; US-2016208340-A1 - TERT Promoter Mutations in Urothelial Neoplasia; US-2016273049-A1 - Systems and methods for analyzing nucleic acid (Inst); US-2017016075-A1 - Neoantigen analysis (Inst); US-2017267760-A1 - Checkpoint Blockade and Microsatellite Instability; US-2018086832-A1 - Hla-restricted epitopes encoded by somatically mutated genes; US-2018135044-A1 - Non-unique barcodes in a genotyping assay (Inst); US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018258490-A1 - Assaying ovarian cyst fluid; US-9976184-B2 - Mutations in pancreatic neoplasms; WO-2010118016-A2 - Digital quantification of dna methylation; WO-2012094401-A2 - Genes frequently altered in pancreatic neuroendocrine tumors; WO-2018071796-A2 - Compositions and methods for identifying functional anti-tumor t cell responses
Travel, Accommodations, Expenses - Merck
 
Francisco Sanchez-Vega
No Relationships to Disclose
 
Nancy E. Kemeny
Research Funding - Amgen
 
Neil Howard Segal
Consulting or Advisory Role - Aduro Biotech; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; CStone Pharmaceuticals; EMD Serono; Gritstone Bio; Horizon Pharma; IFM Therapeutics; Imugene; Kyn therapeutics; Merck; Pfizer; Pieris Pharmaceuticals; PsiOxus Therapeutics; PureTech; Roche/Genentech; Synlogic; TRM Oncology
Research Funding - Bristol-Myers Squibb; Incyte; MedImmune; Merck; Pfizer; Roche/Genentech
 
Zsofia Kinga Stadler
Consulting or Advisory Role - Adverum (I); Alimera Sciences (I); Allergan (I); Biomarin (I); Fortress Biotech (I); Genentech/Roche (I); Novartis (I); Optos (I); Regeneron (I); Regenxbio (I); Spark Therapeutics (I)
 
Anna M. Varghese
Consulting or Advisory Role - Roche (I)
Research Funding - BioMed Valley Discoveries; Bristol-Myers Squibb; Illumina (I); Lilly; Silenseed; Verastem
Travel, Accommodations, Expenses - Roche (I)
 
Efsevia Vakiani
No Relationships to Disclose
 
Marc Ladanyi
Honoraria - Merck (I)
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Merck (I); NCCN/AstraZeneca; Takeda
Research Funding - Helsinn Therapeutics; Loxo (Inst)
 
Michael F. Berger
Consulting or Advisory Role - Roche
Research Funding - Illumina
 
David B. Solit
Stock and Other Ownership Interests - Loxo
Consulting or Advisory Role - Illumina; Intezyne Technologies; Loxo; Pfizer; Vividion Therapeutics
Travel, Accommodations, Expenses - Merck KGaA
 
Jinru Shia
No Relationships to Disclose
 
Leonard B. Saltz
Consulting or Advisory Role - McNeil PPC (I)
Research Funding - Taiho Pharmaceutical
 
Nikolaus D Schultz
No Relationships to Disclose
 
Rona Yaeger
Research Funding - Array BioPharma; GlaxoSmithKline; Novartis
Travel, Accommodations, Expenses - Array BioPharma